CGRP mAb Iv denied for failing step therapy by Humana?

Humana's specific coverage criteria for cgrp mab iv are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Requires Step Therapy for IV CGRP Monoclonal Antibodies — and Why You Can Appeal

Humana's step-therapy (also called "fail-first") policy for IV CGRP monoclonal antibodies requires that a member demonstrate an adequate trial of one or more earlier-line preventive migraine treatments before the plan will authorize this medication. The specific agents and trial durations Humana requires are listed in its published coverage policy — not inferred here, because those requirements change and the policy document is the controlling source. Denials under this basis are common at first authorization but are frequently reversed on appeal when prior treatment history is thoroughly documented.

## Federal Appeal Framework

Step-therapy denials are reviewable under both ACA Section 2719 (external review for non-grandfathered plans) and ERISA Section 503 (full-and-fair review for employer-sponsored plans). You typically have approximately 180 days from the denial notice to file an internal appeal. If Humana upholds the denial internally, you generally have up to four months to request independent external review. Expedited review — with a decision in approximately 72 hours — is available when the standard timeline would seriously jeopardize your health, create severe pain, or significantly impair daily functioning.

Many states have enacted step-therapy override laws that set additional protections; check whether your state's law applies to your specific plan type.

## Concrete Appeal Steps

1. Obtain the denial letter and identify exactly which step-therapy criterion was cited. 2. Pull Humana's published medical/coverage policy for this drug and read the step-therapy requirements line by line. 3. Collect documentation of every prior preventive treatment your prescriber has tried on your behalf — including agents tried, dates started and stopped, doses (from your chart, not self-reported), and the clinical reason for stopping (inadequate response, intolerance, or contraindication). 4. If prior treatments were tried but not adequately documented in chart notes, ask your prescriber to write a retrospective summary. 5. If you have not tried all required agents, your prescriber may attest that one or more are medically contraindicated or clinically inappropriate — this is the standard step-therapy exception basis.

## Documentation to Gather

• Diagnosis and severity documentation: neurologist or headache-specialist notes confirming migraine diagnosis, frequency, and functional impact
• Complete prior-treatment history: medication names, start/stop dates, doses from the chart, and outcome for each agent tried
• Prescriber medical-necessity letter: explains why earlier-line agents failed or are inappropriate and why IV CGRP therapy is now medically necessary
• Applicable guideline reference: a citation to the relevant American Headache Society or American Academy of Neurology guideline supporting the treatment decision (guideline name and organization, not specific numbers)

## Criteria-Mapping Structure

List every step-therapy requirement from Humana's policy in a column. In the adjacent column, enter the specific chart evidence that satisfies each requirement — agent name, trial duration, outcome. If a required agent was not tried, document the clinical reason. Reviewers must have a one-to-one match between policy criterion and chart fact to approve; any gap will be used to uphold the denial.